Asahi Kasei Bioprocess and Axolabs Announce Strategic Partnership to Accelerate Oligonucleotide Therapeutics Development

TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei Bioprocess (AKB) and Axolabs have announced a strategic partnership in the burgeoning field of oligonucleotide therapeutics.